Dr. Ballantyne- one of the foremost lipid experts in the world and recruited by Dr. Braunwald's Heart Disease editorial team- together with a stellar cast of contributors provides all of the scientific and clinical information you need to effectively manage every aspect of dyslipidemia. From basic science to pathogenesis of atherothrombotic disease to risk assessment and the latest therapy options, this new title in the Braunwald's Heart Disease family offers unparalleled up-to-date coverage and expert guidance on lipidology in a straightforward, accessible, and user-friendly style. Plus, Expert Consult functionality gives you anytime, anywhere access to the full text online. Includes full text online access at expertconsult.com. Features the expertise of one of the foremost experts in the field, ensuring you get authoritative guidance with the most definitive knowledge available. Contains extensive clinically relevant information covering risk assessment, therapy, special patient populations, and experimental therapies, including targeting HDL to help you effectively manage any challenges you face. Uses treatment algorithms for easy access to key content. Presents current practice guidelines that assist in the decision-making process.

Mosby, Incorporated

United States, United States of America

Edition 3, Philadelphia, 2023

27. Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias 1
Introduction: Context 1
Biology of Angptl3 2
Rationale for Angptl3 as a Therapeutic Target 2
Clinical Pharmacology of Angptl3 Inhibitors 4
Monoclonal Antibody–Based Therapy: Evinacumab 4
Nucleic Acid–Based Therapies 4
Antisense Oligonucleotide Therapy 4
Small Interfering RNA Therapy 4
GalNAc-Conjugated Nucleic Acid Therapeutics 5
Comparison of Monoclonal Antibody– and Nucleic Acid–Based Therapies 6
Clinical Trials 12
Anti-ANGPTL3 Monoclonal Antibody Therapy 12
Hypertriglyceridemia 12
Hypercholesterolemia 12
Oligonucleotides Targeted at ANGPTL3 mRNA: Vupanorsen and ARO-ANG3 12
Hypertriglyceridemia 12
Hypercholesterolemia 13
Putative Mode of Action of Angptl3 Inhibition on Plasma Lipids and Lipoproteins 13
Therapeutic Perspectives 14
Conclusion: Research Questions 14
Conflicts of Interest 15
Acknowledgment 15
General References 15
Key References 15
Complete References 16

2024-12-16